- Home
- CNTB vs TLSA Comparison
CNTB vs TLSA Comparison
Compare CNTB & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | TLSA |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.4M | 145.1M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CNTB | TLSA |
|---|---|---|
| Price | $0.84 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $5.88 | ★ $8.08 |
| AVG Volume (30 Days) | ★ 1.5M | 518.8K |
| Earning Date | 11-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | $11,291.47 | N/A |
| Revenue Next Year | $74.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $0.76 |
| 52 Week High | $3.82 | $1.96 |
Technical Indicators
Market Signals| Indicator | CNTB | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 39.74 |
| Support Level | $0.73 | $0.90 |
| Resistance Level | $2.62 | $1.17 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 55.72 | 11.82 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.